FDA advisers back approval of Bayer's PAH drug riociguat

An FDA advisory panel recommended the approval of Bayer's riociguat as a treatment for two types of pulmonary arterial hypertension. The agency is expected to issue its decision in October. If approved, the drug would be marketed as Adempas.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations